Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Ashish Srinivasan; Craig Haifer; Lena Thin

doi:10.5694/mja2.51303

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Ashish Srinivasan, Craig Haifer, Lena Thin

Eastern Health Clinical School Research

Research output: Contribution to journal › Letter › Other › peer-review

Original language	English
Pages (from-to)	435
Number of pages	1
Journal	The Medical Journal of Australia
Volume	215
Issue number	9
DOIs	https://doi.org/10.5694/mja2.51303
Publication status	Published - Nov 2021

Keywords

Medicolegal
Pharmaceuticals

Access to Document

10.5694/mja2.51303

Cite this

@article{e89d367eccb546cea840f6bbde312d69,

title = "Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab",

keywords = "Medicolegal, Pharmaceuticals",

author = "Ashish Srinivasan and Craig Haifer and Lena Thin",

year = "2021",

month = nov,

doi = "10.5694/mja2.51303",

language = "English",

volume = "215",

pages = "435",

journal = "The Medical Journal of Australia",

issn = "0025-729X",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

AU - Srinivasan, Ashish

AU - Haifer, Craig

AU - Thin, Lena

PY - 2021/11

Y1 - 2021/11

KW - Medicolegal

KW - Pharmaceuticals

UR - https://www.scopus.com/pages/publications/85116467128

U2 - 10.5694/mja2.51303

DO - 10.5694/mja2.51303

M3 - Letter

C2 - 34622467

AN - SCOPUS:85116467128

SN - 0025-729X

VL - 215

SP - 435

JO - The Medical Journal of Australia

JF - The Medical Journal of Australia

IS - 9

ER -

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Keywords

Access to Document

Other files and links

Cite this